Jodi Euerle Eddy
Known title: SVP, Chief Info & Digital Off.CIK: 0001734900
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Boston Scientific (BSX) Faces Catheter Recall Amid Valuation Debate. Boston Scientific announced a recall of 262,686 catheters because of a life‑threatening tip failure risk. The recall adds pressure as analysts note the company needs clear evidence of its turnaround to justify a better valuation. Truist Securities kept its rating but cut its price target to $51, reflecting a more cautious view. The stock has still moved higher than the broader market, indicating mixed investor reactions.
Transaction History
| ADNT | ▲ Buy | Grant | 8,208 | — | 3/10/2026 | View on chart |
| ADNT | ▲ Buy | Grant | 10,118 | — | 3/11/2025 | View on chart |
| ADNT | ▲ Buy | Grant | 6,225 | — | 3/12/2024 | View on chart |
| BSX | ▼ Sell | Open Market | 2,779 | $125K | 4/1/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 1,426 | $0 | 2/28/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 419 | $19K | 2/28/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 935 | $0 | 2/21/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 275 | $12K | 2/21/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 1,112 | $0 | 2/18/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 327 | $14K | 2/18/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 1,500 | $0 | 2/17/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 441 | $19K | 2/17/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 923 | $0 | 2/15/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 272 | $12K | 2/15/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 3,367 | $0 | 1/1/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 1,179 | $50K | 1/1/2022 | View on chart |
| BSX | ▼ Sell | Open Market | 727 | $33K | 10/22/2021 | View on chart |
| BSX | ▼ Sell | Open Market | 728 | $33K | 9/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Adient Q4 Earnings Set for Nov. 4 as Analysts Trim Targets
Adient will report fourth-quarter and full-year fiscal 2026 results on November 4, 2026. Ahead of this announcement, Barclays and UBS both lowered their price targets to $22 and $23, respectively, while maintaining their ratings. Recent commentary also highlights strong backlog growth driven by onshoring initiatives and new customer wins.
Adient Q4 Earnings Set for Nov. 4 as Analysts Trim Targets. Adient will report fourth-quarter and full-year fiscal 2026 results on November 4, 2026. Ahead of this announcement, Barclays and UBS both lowered their price targets to $22 and $23, respectively, while maintaining their ratings. Recent commentary also highlights strong backlog growth driven by onshoring initiatives and new customer wins.